peptides research grade FAQ

Increase protein intake to 1.2g per pound of lean body mass and add two weekly resistance sessions to prevent lean mass loss. A plateau at week 12 typically reflects NEAT suppression (200–400 calorie daily drop) rather than peptide tolerance. Your body has adapted metabolically. Re-calculate TDEE using indirect calorimetry or a validated equation, then adjust caloric intake to restore a 500–700 calorie deficit. Do not increase peptide dose beyond the prescribed escalation schedule. This compounds GI side effects without addressing the underlying metabolic adaptation.

Drop back to the previous dose step for an additional four weeks, then reattempt escalation at half the standard increment (e.g., increase from 1.0mg to 1.35mg instead of 1.7mg). Persistent nausea beyond eight weeks at a given dose indicates receptor hypersensitivity that slower titration resolves in 70% of cases. Supplement with ginger (1–2g daily) and vitamin B6 (25–50mg daily) to reduce symptom severity. If nausea remains severe after extended titration, switch from tirzepatide to semaglutide. The single-receptor mechanism produces 30% lower nausea incidence.

Clinical evidence shows that most subjects regain two-thirds of lost weight within one year of discontinuing GLP-1 therapy (STEP-1 Extension data). This reflects the fact that peptides correct impaired satiety signaling. When removed, ghrelin elevation and leptin suppression return. Transition planning with a prescribing physician is essential: taper dose over 8–12 weeks rather than stopping abruptly, increase protein intake to 1.0g per pound of body weight, and establish a structured resistance training program to preserve metabolic rate. Some subjects maintain loss on a lower maintenance dose (0.5mg semaglutide weekly or 5mg tirzepatide weekly) indefinitely.

Yes, and the mechanisms are complementary. Finasteride prevents further miniaturisation by blocking DHT, while peptides attempt to reverse existing miniaturisation through growth factor signaling. A 2020 pilot study in International Journal of Trichology found participants using finasteride + topical GHK-Cu showed 27% greater terminal hair density increase at 24 weeks compared to finasteride alone. The peptide addresses follicles already damaged by years of DHT exposure that finasteride can no longer help.

Extend the protocol to 20 weeks before concluding failure. Follicles in late telogen phase require 16+ weeks of continuous peptide exposure to shift into anagen. If you're using topical GHK-Cu without microneedling, add microneedling (1.5mm depth) every 14 days to increase dermal penetration from under 7% to above 40%. Research from Journal of Cosmetic Dermatology found participants who added microneedling at week 12 saw delayed but measurable density improvements by week 24, suggesting the peptide was present but bioavailability was the limiting factor.

Discard it immediately. Cloudiness indicates protein aggregation or bacterial contamination, both of which render the peptide biologically inactive. Lyophilised peptides must be reconstituted with sterile bacteriostatic water at controlled temperature (15–20°C), and the vial should never be shaken, only gently swirled. If cloudiness appears after refrigeration, the peptide likely experienced a temperature excursion during shipping or storage that caused irreversible denaturation. Quality peptide suppliers like Real Peptides ship with cold packs and temperature indicators to prevent this issue.